Century Therapeutics (IPSC) Cash from Financing Activities (2020 - 2026)
Century Therapeutics (IPSC) posted quarterly Cash from Financing Activities of $126.6 million for Q1 2026, up 105419.17% year-over-year from N/an in Q1 2025, and up 238811.32% quarter-over-quarter from $53000.0 in Q4 2025.
Powered by 
Analysis
Century Therapeutics (IPSC) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has reported Cash from Financing Activities for 7 consecutive years, with $126.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 105419.17% year-over-year to $126.6 million; the TTM figure through Mar 2026 stood at $126.7 million (up 124.25% YoY), while the FY2025 annual figure was $173000.0, down 99.77% from the prior year.
- Cash from Financing Activities improved to $126.6 million in Q1 2026 per IPSC's latest filing, from $53000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $126.6 million in Q1 2026 and bottomed at -$10.1 million in Q2 2023.
- Historically, Cash from Financing Activities has averaged $14.6 million across 5 years, with a median of $137000.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities plunged 21177.08% — and 2026, when it jumped 105419.17%.
- Century Therapeutics' Cash from Financing Activities stood at $95000.0 in 2022, then slumped by 474.74% to -$356000.0 in 2023, then sank by 69.1% to -$602000.0 in 2024, then soared by 108.8% to $53000.0 in 2025, then soared by 238811.32% to $126.6 million in 2026.
- Business Quant data shows IPSC's Cash from Financing Activities at $126.6 million in Q1 2026, $53000.0 in Q4 2025, and $120000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Century Therapeutics | 440.37 Mn | 180.29 Mn | - | 311,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 311,000.00 |
| Mar 31, 2026 | 126.62 Mn |
| Dec 31, 2025 | 53,000.00 |
| Mar 31, 2025 | 120,000.00 |
| Dec 31, 2024 | -602,000.00 |
| Sep 30, 2024 | 273,000.00 |
| Jun 30, 2024 | 56.70 Mn |
| Mar 31, 2024 | 18.20 Mn |
| Dec 31, 2023 | -356,000.00 |
| Sep 30, 2023 | 300,000.00 |
| Jun 30, 2023 | -10.12 Mn |
| Mar 31, 2023 | 448,000.00 |
| Dec 31, 2022 | 95,000.00 |
| Sep 30, 2022 | 137,000.00 |
| Jun 30, 2022 | 48,000.00 |
| Mar 31, 2022 | 26.88 Mn |
| Dec 31, 2021 | 106,000.00 |
| Sep 30, 2021 | -466,000.00 |
| Jun 30, 2021 | 224.65 Mn |
| Mar 31, 2021 | 193.49 Mn |